Primary Peritoneal Carcinoma Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00093626Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerTreatment